Cellectis to Report First Quarter Financial Results on May 12, 2025

Rhea-AI Summary

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapy development, has announced it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the US market closes. The financial results will be accessible through a press release in the Investors section of the company's website. Unlike typical earnings releases, Cellectis will not host a conference call to discuss the results, though their investor relations team will remain available to address questions via email at investors@cellectis.com.

News Market Reaction

-3.48%

1 alert

-3.48% News Effect

On the day this news was published, CLLS declined 3.48%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market.

The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/

Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com     

About Cellectis 

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:    

Media contacts:       
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

 

Attachment

• 20250506_FY 2024 earnings call announcement_ENGLISH

FAQ

When will Cellectis (CLLS) release its Q1 2025 earnings?

Cellectis will release its Q1 2025 financial results on Monday, May 12, 2025, after the US market closes.

Will Cellectis (CLLS) host an earnings call for Q1 2025 results?

No, Cellectis will not host a conference call to discuss the Q1 2025 results, but investors can direct questions to investors@cellectis.com.

Where can I find Cellectis (CLLS) Q1 2025 earnings release?

The earnings press release will be available in the Investors section of Cellectis' website at https://www.cellectis.com/en/investors/press-releases/

What does Cellectis (CLLS) specialize in?

Cellectis is a clinical-stage biotechnology company that uses its pioneering gene-editing platform to develop life-saving cell and gene therapies.